Abstract-In many real-world applications, it is important to mine causal relationships where an event or event pattern causes certain outcomes with low probability. Discovering this kind of causal relationships can help us prevent or correct negative outcomes caused by their antecedents. In this paper, we propose an innovative data mining framework and apply it to mine potential causal associations in electronic patient data sets where the drug-related events of interest occur infrequently. Specifically, we created a novel interestingness measure, exclusive causal-leverage, based on a computational, fuzzy recognition-primed decision (RPD) model that we previously developed. On the basis of this new measure, a data mining algorithm was developed to mine the causal relationship between drugs and their associated adverse drug reactions (ADRs). The algorithm was tested on real patient data retrieved from the Veterans Affairs Medical Center in Detroit, Michigan. The retrieved data included 16,206 patients (15,605 male, 601 female). The exclusive causal-leverage was employed to rank the potential causal associations between each of the three selected drugs (i.e., enalapril, pravastatin, and rosuvastatin) and 3,954 recorded symptoms, each of which corresponded to a potential ADR. The top 10 drug-symptom pairs for each drug were evaluated by the physicians on our project team. The numbers of symptoms considered as likely real ADRs for enalapril, pravastatin, and rosuvastatin were 8, 7, and 6, respectively. These preliminary results indicate the usefulness of our method in finding potential ADR signal pairs for further analysis (e.g., epidemiology study) and investigation (e.g., case review) by drug safety professionals.
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INTRODUCTION
F INDING causal associations between two events or sets of events with relatively low frequency is very useful for various real-world applications. For example, a drug used at an appropriate dose may cause one or more adverse drug reactions (ADRs), although the probability is low. Discovering this kind of causal relationships can help us prevent or correct negative outcomes caused by its antecedents. However, mining these relationships is challenging due to the difficulty of capturing causality among events and the infrequent nature of the events of interest in these applications.
In this paper, we try to employ a knowledge-based approach to capture the degree of causality of an event pair within each sequence since the determination of causality is often ultimately application or domain dependent. We then develop an interestingness measure that incorporates the causalities across all the sequences in a database. Our study was motivated by the need of discovering ADR signals in postmarketing surveillance, even though the proposed framework can be applied to many different applications. ADRs represent a serious world-wide problem [1] , [2] . They can complicate a patient's medical condition or contribute to increased morbidity, even death. Studies have shown that ADRs contribute to about 5 percent of all hospital admissions and represent the fifth commonest cause of death in hospitals [3] .
Even though premarketing clinical trials are required for all new drugs before they are approved for marketing, these trials are necessarily limited in sample-size and duration, and thus are not capable of detecting rare ADRs. In general, an ADR cannot be recognized by these trials if its occurrence rate is less than 0.1 percent [1] . Therefore, drug safety depends heavily on postmarketing surveillance; that is, the monitoring of impacts of medicines once they have been made available to consumers. In the US, current postmarketing surveillance methods primarily rely on the FDA's spontaneous reporting system MedWatch. Because ADR reports are filed at the discretion of the users of the system, there is gross underreporting [4] , [5] . Consequently, the current approach may require years to identify and withdraw problematic drugs from the market, and result in unnecessary mortality, morbidity, and cost of healthcare. Studies have shown that only half of newly discovered serious ADRs are detected and documented in the Physician's Desk Reference within 7 years after drug approval [6] .
Systematic methods for the detection of suspected safety problems from spontaneous reports have been studied and practically implemented. For example, the FDA currently adopts a data mining algorithm called Multi-item Gamma Poissson Shrinker [7] for detecting potential signals from its spontaneous reports. Another important signal detection strategy is known as the Bayesian Confidence Propagation Neural Network that has been used by the Uppsala Monitoring Center in routine pharmacovigilance with its World Health Organization database [8] . Various other methods such as proportional reporting ratios [9] , empirical Bayes screening [10] , and reporting odds ratios [11] have been used in the spontaneous reporting centers of other nations (e.g., England and Australian). These methods have shown better performance than traditional methods. However, the performance of these techniques could be highly situation dependent due to the weaknesses and potential biases inherent in spontaneous reporting [12] .
As electronic patient records become more and more easily accessible in various health organizations such as hospitals, medical centers, and insurance companies, they provide a new source of information that has great potential to generate ADR signals much earlier [13] , [14] . Note that each patient case can be considered as an event sequence where various events such as drug prescription, occurrence of a symptom and lab test occur at different times. In the literature, there exist a couple of studies [14] , [15] that attempted to find the associations between drugs and potential ADRs by mining their temporal relationships. That is, they tried to mine temporal association rules (represented as X ! T Y ) where Y occurs after X within a time window of length T . These studies obtained promising results based on administrative health data. However, temporal association was the only parameter used for linking a symptom with a drug within each patient case in their work. Temporal association assumes that cause precedes effect. Other parameters such as dechallenge and rechallenge can also give direct or indirect cues of the potential causal association of a drug-symptom pair. Dechallenge is defined as the relationship between withdrawal of the drug and abatement of the adverse effect. Rechallenge describes the relationship between reintroduction of the drug followed by recurrence of the adverse event. In addition, their approaches suffer from the sharp boundary problem. On the one hand, the symptom events near the time boundaries are either ignored or overemphasized. On the other hand, two symptom events contribute equally to the interestingness measure as long as they occur within the hazard period T . That is, the length of the time duration between exposure to the drug and occurrence of the symptom has no effect on the interestingness measure. This is not true in reality because if an ADR symptom occurs within a shorter period, it is usually more likely to be caused by the drug.
To more effectively mine infrequent causal associations, it is necessary to develop a new data mining framework. The this paper is a substantial extension of our previous work [16] , [17] where an interestingness measure called causal-leverage was developed on the basis of a computational fuzzy recognition-primed decision (RPD) model [18] we previously developed. In this paper, we focus on mining infrequent causal associations. We significantly extended our previous work in both theories and experiments.
1. We developed and incorporated an exclusion mechanism that can effectively reduce the undesirable effects caused by frequent events. Our new measure is named exclusive causal-leverage measure. 2. We proposed a data mining algorithm to mine ADR signal pairs from electronic patient database based on the new measure. The algorithm's computational complexity is analyzed. 3. We compared our new exclusive causal-leverage measure with our previously proposed causal-leverage measure as well as two traditional measures in the literature: leverage and risk ratio. 4. To establish the superiority of our new measure, we did extensive experiments. In our previous work, we tested the effectiveness of the causal-leverage measure using a single drug in the experiment. In this paper, we selected three drugs and evaluated the top 10 ICD-9 (International Classification of Diseases, ninth Revision) codes ranked by the exclusive causalleverage measure for each drug. We also tested how the length of hazard period T affects the performance of the exclusive causal-leverage measure.
RELATED WORK IN THE LITERATURE
Discovering the association between two event sets is an active and important area of data mining research [19] , [20] , [21] , [22] . Many measures have been proposed to mine association rules in the form of X ! Y , where X and Y are two event sets and they are disjoint (i.e., X \ Y ¼ ). For instance, the support and confidence measures were the original interestingness measures proposed for association rules [23] . The support of an association rule supp(X ! Y ) is the proportion of sequences in which both X and Y occur at least once, among all the event sequences. The confidence of an association rule is defined as conf(
, where supp(X ! ) is the proportion of sequences that contain X. Given these two measures, the association rule mining problem can be formalized as finding those rules whose support and confidence are greater than prespecified thresholds minsupp and minconf, respectively. In the literature, researchers have also proposed various other interestingness measures such as IS [24] , Klosgen's measure [25] , weighted relative accuracy [26] , and so on. Originated from areas such as probability, statistics, or information theory, these traditional interestingness measures are primarily designed for finding frequent association rules. Thus, they have limited capability in discovering patterns that occur infrequently.
There exist some works on rare eventset (or item set) mining in the literature [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] . A straightforward approach to discovering infrequent eventsets is to relax the uniform minimal support criterion (i.e., minsupp) as indicated in [27] . One drawback of this mining approach is the extremely high computational cost [28] , [29] , [36] . In addition, if this approach was used to discover rare events like ADRs, thresholds minsupp and minconf would have to be set very small, possibly leading to a lot of false associations [14] .
A couple of studies attempted to use a less uniform support criteria [28] , [29] , [30] . Yun et al. adopted a relative support (a rate against the relative frequency of the data existing in a database) approach [29] , while Liu and his colleagues proposed a method that relied on multiple minimal support thresholds specified by users [28] . These approaches output all frequent eventsets and association rules together with a subset of all infrequent ones.
Several other studies explored rare eventsets (rules) with support lower than the threshold [31] , [32] , [33] , [34] , [35] . These studies implemented different strategies to traverse the power set lattice of a data set. For example, some of them take a bottom-up approach to moving across the lattice [31] , [32] , [35] , while another algorithm named Rarity (proposed by Troiano et al.) takes a top-down method [33] . Koh and Rountree proposed an algorithm called AprioriInverse where sporadic rules are discovered by simply discarding all eventsets above a support threshold [34] .
The above approaches to detection of rare association rules are based on traditional interestingness measures like support and confidence. One pitfall of these measures is that they simply find the statistical correlation between X and Y . For example, the confidence of an association rule X ! Y determines how frequently Y appears in those event sequences that contain X. That is, traditional measures like confidence try to find the statistical significance of the coexistence of two eventsets. They do not indicate any temporal relationship between X and Y . In addition, they are not able to capture the causal relationships between two event sets. They do not specify whether X causes Y , or vice versa, or a third event causes the coexistence of X and Y . Hence, statistical associations established by traditional measures may or may not represent temporal or causal associations.
Causal modeling and inference have been widely studied in the field of machine learning and traditional probability and statistics theory [37] , [38] , [39] . Compared with statistical co-existence, causal relationships have a couple of unique properties. First, there is an intrinsic asymmetry in a cause-effect relationship. That is, when saying event X causes event Y , one would not expect X to be influenced by Y . Second, the concept of causality is linked to time dependencies. That is, the causes must precede their effects. Researchers have proposed various models to model causal relationships for the purpose of prediction or data modeling (i.e., estimation of a probability law that has generated the data). These models include artificial neural networks [40] , Markov models [41] , various graphical models [38] , [39] , etc. One of the most famous models is Pearl's causal model where causal modeling and inferences are based on representations by means of directed acyclic graphs (DAGs) [38] . For a more extensive and detailed review about the state of the art of causality, readers are referred to a recent survey paper [37] .
With a surge of interest in association rule mining in recent years, some of the above models have been borrowed to mine the causal relationships between two events or eventsets. For instance, Bayesian network and its variants have been adapted to mine causal structures in a couple of studies [42] , [43] . One criticism of Bayesian analysis is its requirement to specify prior distributions for all variables, which can be very difficult since, in many cases, prior knowledge is vague or nonexistent, or can be tedious if the number of variables is large [37] , [38] . Silverstein et al. proposed a constraint-based algorithm that narrowed down the search space and thus made the mining process more scalable [39] . In addition, Hidden Markov Models (HMMs) have been utilized to predict protein structures and analyze genome sequences based on massive amounts of observed data [44] , [45] . However, these approaches are inherently probabilitybased and designed to find frequent patterns. Thus, they have limited capability in discovering infrequent associations.
BACKGROUND ON FUZZY RPD MODEL
The RPD model [40] , [46] represents a popular cognitive decision model. It is particularly useful for modeling how human experts make decisions based on their prior experiences. It was found that about 50 to 80 percent of all decisions were made in this way [41] . The original RPD model is descriptive and is not directly implementable on a computer. Hence, we developed a fuzzy RPD model [18] , which is not only computational but also capable of handling vague and subjective information using fuzzy logic [47] , [48] .
Experiences play a key role in the RPD model. The ADR detection experiences were acquired through the joint efforts of our engineering and medical team members after careful analysis of the relevant literature. According to the classification scheme in [49] , a particular pattern of cue values characterizes a specific degree of causality which may require certain courses of action to handle the ADR. Therefore, we can define four experiences, each of which is associated with a degree of causality (i.e., very likely, probable, possible, and unlikely). These experiences were stored in an experience knowledge base (EKB). Fig. 1 presents a sample experience illustrated in natural language for easier understanding. As shown, an experience consists of four componentscues, goals, actions, and expectancies. Cues represent the higher level information (synthesized from elementary or environmental data) that a decision maker must pay attention to. Expectancies describe what will happen next as the current situation continues to evolve in a changing context. Goals represent an end state that the decision maker is trying to achieve. Actions represent a set of potential decisions that the decision maker can take in the current situation. Cues are used to match the current situation with prior experiences and determine which experience can be reused to solve a new problem. This sample experience has four cues: temporal association, dechallenge, rechallenge, and other explanation. The first three cues have been explained in Introduction. Other explanations denote alternative explanations by concurrent disease or other drugs. The type of cue could be quantitative, nominal or fuzzy in the proposed computational fuzzy RPD model. For instance, the cue "temporal association" may have fuzzy values (e.g., unlikely, possible, likely). The weights for these cues are design parameters and are assigned by domain experts. Table 1 shows how the four cues are related to degree of causality of a signal pair in the four experiences. These mappings were given by the physicians in our research project. For instance, when cues temporal association, rechallenge and dechallenge have fuzzy cue values possible, unlikely, and possible, respectively, and there is no other explanations, this cue value pattern represents a possible causal association between the drug of interest and the suspected ADR from the perspective of a physician. In general, these mappings are determined by domain experts.
After representing the experiences, the next step is to extract the cue values from elementary data for the current situation (e.g., a new patient case in which a drug-symptom pair need to be evaluated). Fuzzy rules and fuzzy reasoning are used to achieve this task. For example, to obtain the fuzzy value of temporal association, one of the fuzzy rules of the type "if the time duration between taking the drug and the occurrence of the adverse event is short, then temporal association is likely" is used. An embedded fuzzy inference engine is employed to perform fuzzy reasoning. The inference engine is what drives the RPD model, updating cues once new information is detected, and monitoring expectancies and goals. After the cue values of the current situation are known, similarity measures are applied to measure the degree of matching between the current situation and prior experiences. The actions in the most matching experience are then used to solve the current problem. For more details of the fuzzy RPD model as well as concrete examples, the reader is referred to our previous work [18] .
The fuzzy RPD model was preliminarily validated in our previous study [18] by using it to calculate the extent of causality between cisapride and some of its adverse effects for 100 simulated patients created based on the profiles of 1,015 patients of the VA Medical Center. The simulated patients were used because we found that the number of apparent signal pairs of potential interesting symptoms (i.e., cisapride and Torsades de Pointe and/or syncope) in the real patient data was very limited. Therefore, we used the real patients to create simulated patient cases, all of which containing drug-symptom pairs of interest with various degrees of causality. The model's validity was then established by comparing the decisions made by the model and those by two independent experienced physicians for the 100 simulated patients. The levels of agreements were measured by the weighted Kappa statistic, which is a measure of agreement between two raters after chance agreement is controlled. The results suggested good to excellent agreements [50] .
DEVELOPING A NEW MEASURE AND APPLYING IT TO SEARCHING ADR SIGNAL PAIRS
In this section, we first introduce a new measure we recently developed. We then discuss how to mine potential ADRs from electronic patient records using this measure.
A New Exclusive Causal-Leverage Measure
We use <X; Y > and C <X;Y > to represent a pair of events and the degree of causality of the pair in a sequence, respectively. C <X;Y > is calculated by matching the cue values extracted from a sequence with the cue values of the defined experiences, each of which corresponds to a unique category of causality (i.e., very likely, probable, possible, and unlikely). Specifically, we use a vector V ¼ if cue i is fuzzy value:
In the above definition, the cue similarity is set 0 if either of the cue values is unknown. The function overlap() is defined as 
That is, for nominal cue values, the similarity is 1 if the cue values are equal; otherwise, it is 0. Computing the similarity for quantitative cue values involves distance measure normalized_diff :
where Á i ¼ a i À b i is employed to normalize the cue difference, and a i and b i are the maximum and minimum values for cue i, respectively. The last expression in the above formula, fuzzy simðc i ; c 0 i Þ, deals with cues represented by fuzzy sets. Let cue i be defined on the universe of discourse X and x be an element of X. In this case, fuzzy cue values c i and c The similarity between two sets of cue values V and V 0 is named as global similarity S G ðV ; V 0 ). It is defined as the weighted sum of all the local similarities with respect to each pair of cue values. That is,
where w i 2 ½0; 1 is the weight for cue i, which represents the relative significance of the cue and is assigned by the user. The above global similarity is used to find the most matching experience whose associated causality category can characterize the causal association of a pair of interest in a particular event sequence. We use this approach to obtain a similarity value between the current pair and each of the experiences. After that, these similarity values are normalized so that their sum is equal to 1. These normalized values are then used to represent the membership values of corresponding categories for the pair of interest in a particular sequence. For example, if the normalized similarity value between a pair and the experience exhibiting "possible" association is 0.6, we would say the causality of the pair is "possible" with a membership value of 0.6 in that sequence. If we use d and s to represent a drug and a symptom, respectively, Table 2 gives a couple of sample drug-symptom pairs as well as their membership values related to each causality category for the patient cases that contain the pairs. Note that, given a particular drugsymptom pair, there may exist none, one, or multiple patient cases that contain this pair. On the other hand, the same patient case may contain multiple different pairs. Patient In general, if there exist m experiences that classifies the causality between X and Y into m distinctive categories, the degree of causality is defined as
where i is the membership of the ith causality category for the pair, and w i represent the corresponding weight when converging all the causality categories into one. Moreover,
The selection of w i is based on two considerations. First, causality categories representing stronger causal associations should have higher weights. That is, if we assume the causality levels represented by m experience are in a decreasing order, then w m > Á Á Á > w 2 > w 1 must be satisfied, where w m and w 1 correspond to the highest and lowest causality levels, respectively. Second, the range of C <X;Y > should be [0, 1] . That is, C <X;Y > should be 0 for the extreme situation ¼ f0; . . . ; 0; 1g where the evidence in a sequence strongly shows "unlikely" association of the pair. If all the evidence in the patient supports "very likely" association (i.e., ¼ f1; 0 Á Á Á 0g), C <X;Y > should be 1. Otherwise, C <X;Y > is between 0 and 1. In general, the weight for the ith causality category is calculated by
where m ! i ! 1. For example, if there are four causality categories (i.e., m ¼ 4), then the set of weights for them would be 1:0; 0:667; 0:333; 0:0 f g . One can see that the computed C <X;Y > using these weights satisfies the above two criterions. 
where n is the number of sequences that contain the pair. N is the total number of sequences in the database. The advantage of this definition is that the degree of causality is incorporated into the measure such that sequences exhibiting higher causality will contribute more to the measure. Based on the above definition of the support of a CAR, we define an interestingness measure called causal-leverage:
where suppðX ! c Þ is the proportion of sequences whose votes are greater than 0 with respect to the pair <X; Y >. supp(! Y ) is the proportion of sequences that contain Y . This measure extends the traditional leverage measure (i.e.,
by incorporating the degree of causality of the pair among all sequences into it. With better capability of capturing causal associations, the causal-leverage measure can be employed to mine the causal association of pair <X; Y > given a collection of event sequences. However, its ability of discovering the causal associations between drugs and their potential ADRs is still limited because of the complexity and special characteristics of electronic patient data. Recall that the degree of causal association of a pair within a particular patient case is determined by four cues: temporal association, rechallenge dechallenge, and other explanations. One can see that three of them are time related. For a particular pair, their values can be abstracted from a specific patient case using fuzzy rules and these values collectively determine the degree of causal association of the pair in the patient case. However, the obtained cue values may not really represent the actual causal association of the pair due to the complexity of the electronic patient data. One of the complexities is that frequently prescribed drugs are easily temporally associated with any symptom by coincidence. For example, if the hazard period T is equal to 90 days and the start date of a drug appears once every two months within the same case, then the drug has temporal association with any symptom existed in the patient case. Similarly, a particular drug tends to coincidently form temporal association with symptoms (e.g., fever) caused by common diseases. Note that symptoms of a potential ADR cannot be differentiated from those of an underlying disease, both of which are encoded using the same ICD-9 codes in electronic patient databases. For a drug-symptom pair, the associated symptom is possibly caused either by a drug or by a disease after the drug is started. If both a drug and a symptom have high frequencies in a health database, they can even easily form rechallenge by coincidence. As a result, the obtained causal-leverage value can be high for the pair even though this value does not imply any degree of causality. Therefore, it is necessary to find an exclusion mechanism to reduce the undesirable effects caused by high frequent events (e.g., either drugs or symptoms).
Intuitively, if a high frequent event Y randomly occurs after another event X within time period T , then it should have the same chance to also occur before X within the same period T among many event sequences. Case1 in Fig. 2 demonstrates a pattern where the symptom s 1 occurs before the drug d 1 within time period T . A reasonable explanation of this pattern is that the underlying disease of the symptom s 1 causes the prescription of the drug d 1 . Case2 indicates a pattern where the symptom s 1 occurs after the drug d 1 within time period T . If we look at Case2 only, a reasonable explanation could be that the symptom s 1 represents a possible ADR caused by the drug d 1 since they exhibit reasonable temporal association. However, if we look at these two patient cases together, it is more likely that the symptom s 1 simply occurs randomly. In this case, both the pair <d 1 , s 1 > and its reversed pair <s 1 , d 1 > exhibit temporal associations in various patient cases. In some cases, the above two patterns can coexist in the same patient case as shown in
has temporal and rechallenge relationship with s 1 since their temporal association occurs twice along the time. However, this pattern can be explained differently. For example, the second d 1 occurs after the first s 1 , which can be explained as the underlying disease of the symptom causing the prescription of the drug. The temporal association between s 1 and d 1 also occurs twice and they also exhibit rechallenge relationship. Considering all these four types of patterns together, if drugs and/or symptoms occur randomly and frequently, they may falsely form temporal association and rechallenge relationships. However, the number of cases exhibiting these relationships for a pair <drug, symptom> and that for its reversed pair (i.e., <symptom, drug>) should be similar. high the frequency of the pair is. Otherwise, if X causes Y , the former should be greater than the latter. On the other hand, if Y causes X, then the former should be smaller than the latter. Hence, we define an exclusive causal-leverage measure as below
If this measure has a positive value, it denotes that X has causality with Y . The bigger the value, the stronger the causal association. If its value is negative, it indicates a reverse causality. Otherwise, a value close to zero is a sign of no causal association between X and Y . Thus, this measure not only provides a way to quantify the degree of causal association but also excludes undesirable effects caused by high-frequency events that occur randomly.
Mining ADR Signal Pairs from Electronic Patient Databases
Drugs and their associated ADRs have causal relationships. In this section, we examine how to search for potential ADR signal pairs from an electronic patient database using the above exclusive causal-leverage measure. We assume that patient data are stored in relational tables in a database and can be retrieved using database language like structured query language (SQL). These tables are linked through patient identification numbers (PIDs). We also assume that the drug-related data and symptom-related data are stored in two tables called Patient Drug Table and Patient  Symptom Table, respectively. Fig. 3 shows an overall picture of the data mining algorithm. First, preprocessing is needed to get two types of information: 1) a list of all drugs Dðd 1 ; d 2 ; . . . ; d m ) in the database and the support count for each drug; 2) a list of all symptoms Sðs 1 ; s 2 ; . . . ; s n ) in the database and the support count for each symptom. The lists of drugs and symptoms are needed to form all possible drug-symptom pairs whose causal strengths will be assessed. Since a patient database normally only contains a subset of all drugs on the market and a subset of all symptoms, it is necessary to search the Patient Drug Table and the Patient Symptom Table to get the drugs and symptoms covered by the database. Using the discovered drugs and symptoms in the database (instead of all drugs on the market and all available symptoms) can avoid forming unnecessary pairs, which will reduce the computational complexity of the data mining algorithm. In addition, the support count for each drug or symptom will be used to calculate the exclusive causal-leverage value for related pairs. Hence, their values also need to be computed. Algorithm 1 shows how to search a database (DB) for the list of drugs and the support count for each drug. The discovered drugs and their support counts are stored in a hash table as shown in Fig 4a. Initially, the hash table is empty. We use D k to represent the set of drugs taken by the kth patient p k in the database. For each patient, we first retrieve all the drugs taken the patient. For each of these drugs, we then check whether the hash table contains the drug. If the hash table does not contain the drug, the drug's support count is set as 1, and both the drug and its support count are added to the hash table. Otherwise, the drug's support count is increased by 1. After all the patient cases are searched, the hash table is returned. Note that, when calculating the support count for a drug, it is counted only once for one patient case even if the drug appears several times in that patient case. One can see that the computational complexity of this searching process can be affected by the total number of patients N in the database and the average number of drugs taken by a patient. The later is normally determined by the type of patients in the database. For instance, old patients often have multiple diseases and thus may take multiple drugs either at the same time or different times. The algorithm used to search the Patient Symptom Table for a list of symptoms covered by the database as well as the support count for every symptom (Fig 4b) is similar to Algorithm 1. If users are only interested in mining the potential ADRs of a particular drug or a couple of drugs, the users can specify the drugs of interest. Similarly, the users can also specify the list of symptoms if they want to analyze which drugs can cause the symptoms of interest. In both cases, however, the Patient Drug Table and the Patient  Symptom Table still need to be searched in order to get the support count for each drug or symptom.
After getting the list of drugs Dðd 1 ; d 2 ; . . . ; d m Þ and the list of symptoms Sðs 1 ; s 2 ; . . . ; s n Þ, the next step is to generate all the possible pairs, each of which represents a CAR. Algorithm 2 shows the process for pair generation and evaluation. Please note that most existing data mining methods mine all interesting association rules that combine all possible events or items in a database. We are only interested in mining drug-symptom pairs that can be easily generated, given D and S. That is, we are not interested in other patterns like drug-drug pairs, symptom-symptom pairs or combinations of multiple drugs and symptoms. Thus, our algorithm generates a much fewer number of candidate rules, which implies much less complexity. The complexity of this pair generation process is O(m Â n) where m and n are the number of drugs and symptoms, respectively. In addition, since we are interested in mining infrequent patterns, it is inappropriate to prune pairs using the support measure (i.e., support > minsupp). However, in postmarketing surveillance, a signal pair generated by a data mining method is generally not considered as valid if only one or two patient cases contain the pair [9] . Therefore, we utilize a minimum support count mincount = 3 (instead of minsupp) to further reduce the number pairs that will be evaluated. Specifically, we retrieve the PIDs of those patient cases that contain both the drug and the symptom of each pair. This is done by sending a SQL statement to query the database. Modern database management systems can utilize optimization techniques like index to speed up this process. If the number of PIDs that support a pair is greater than or equal to mincount (Line 4 of Algorithm 2), the pair is evaluated. To evaluate the strength of the causal association of the pair, its causal-leverage value is first computed. Then, the pair is reversed. That is, the pair <d i ; s j > becomes <s j , d i >. The reverse causal-leverage value of pair <d i ; s j > is equal to the causal-leverage value of its reversed pair <s j ; d i >. After that, the exclusive causal-leverage value of the pair is computed by subtracting its reverse causal-leverage value from its normal causal-leverage value. end if 10: end for 11: end for Algorithm 3 shows how to compute the causal-leverage value of a general pair between event X and Y . Both X and Y could be either drug event or symptom event. First, the drug or symptom hash table is searched in order to get the support count for event Y . Then, for each PID that supports the pair, a process called cue abstraction is used to extract a set cue values V from the related patient case. Specifically, a list of drug start dates and a list of symptom dates are retrieved from the Patient Drug Table and the Patient  Symptom Table, respectively. Note that, since each patient case records the patient's history for a long period of time, the same drug may be prescribed many times and thus multiple drug start dates may exist within one patient case. Similarly, there may exist multiple symptom dates for the symptom within the same patient case. Therefore, we must compare each start date of the drug with each symptom date of the symptom in order to obtain interested temporal patterns for the pair within the case. The complexity of this process is OðL d Â L s Þ, where L d and L s are the length of the list of drug start dates and the length of the symptom dates, respectively. L d and L s often depend on the characteristics of the patient. For example, a patient with chronic diseases tends to take the same drug for many times and have repeated symptoms. After getting the temporal patterns, cue values for temporal association, rechallenge, and dechallenge are derived from these patterns using fuzzy rules. Note that, in order to make our algorithm more generic, the cue other explanations was not utilized in this study since it is drug dependent. Readers are referred to our previous paper for specific fuzzy rules that were used in this process [16] . 
for each PID that supports the pair do 3:
V ¼ cue-abstractionðPIDÞ 4:
C <X;Y > ¼ weightedSumðSV 0 ; WÞ {W: weights calculated by Eq (8)} 7:
if ðC <X;Y > > 0Þ then 8:
accumulatedV otesþ ¼ C <X;Y > 9:
contributionCases þ þ{number of cases whose votes are greater than 0} 10:
end if 11:
end for 12: suppðX ! c Y Þ ¼ accumulatedV otes=N
After the set of cue values V of the pair are extracted from the related patient case, similarity values are computed between V and each set of cue values V 0 in the experience knowledge base. This step is also called feature matching in the Fuzzy RPD model. These similarity values are then normalized so that they are transformed to the format shown in Table 2 . After that, the degree of causality C <X;Y > within the current patient is computed. If C <X;Y > is greater than 0, it is added to the accumulated votes and the number of cases whose votes are greater than 0 is increased by one. After the above computation is done for all the supporting cases of the pair, the causal-leverage value of the pair is computed (refer to (10)) and returned.
Finally, we rank all the pairs in a decreasing order according to their exclusive causal-leverage values after all these values are computed. The higher the value, the more likely a causal association exists in the pair or CAR.
EXPERIMENTS

Experiment Data
Our experiment data were from Veterans Affairs Medical Center in Detroit, Michigan. We were interested in two classes of drugs: statin drugs and angiotensin-converting enzyme inhibitors (ACEI) drugs. Deidentified electronic data of all the patients who received at least one of the drugs of our interest during the time period from 4 September 2007 to 16 September 2009 were retrieved. "Event" data such as dispensing of drug, office visits, and certain laboratory tests were retrieved for all the patients. For each event certain details were obtained. For example, the data for dispensing of drug include the name of the drug, quantity of the drug dispensed, dose of the drug, drug start date, drug schedule, and the number of refills.
The retrieved data included 16,206 patients. 15,605 (96.3 percent) were male, and 601 (3.7 percent) were female. Their average age was 68.0. The drugs enalapril, pravastatin, and rosuvastatin were selected to test the proposed data mining framework. Pravastatin and rosuvastatin are both statin drugs, and enalapril is an ACEI drug. These three drugs allow us to examine the effectiveness of our data mining framework in identifying potential ADRs for drugs both in the same drug class and in different drug classes. The total number of patients who took one of the three drugs enalapril, pravastatin, and rosuvastatin at least once is 1,021, 1,383, and 882, respectively. Note that multiple drugs might be prescribed for the same patient either at the same date or different dates along time. The total number of distinctive ICD-9 codes was 3,954 in the data. Each code represented a potential ADR that might be causally associated with any drug.
The data were stored in five relational tables in a Microsoft Access database. These tables contained patients' demographic data, visit data, diagnostic data, drug-related data, and laboratory data. SQL was used to query the tables and obtain desired information. The query results were returned to Java programs that implemented the data mining algorithm. Fuzzy sets and fuzzy rules were coded using Fuzzyjess [52] , a Java-based fuzzy inference engine. Table 3 gives the causal-leverage, reverse causal-leverage, and exclusive causal_leverage between drug enalapril and each of seven ICD-9 codes: 276.7 (hyperkalemia), 366.02 (post subcaps polar cataract), 428.0 (congestive heart failure), 327.27 (central sleep apnea in conditions classified elsewhere), 305.60 (cocaine abuse unspecified), 275.42 (Hypercalcemia), and 525.9 (unspecified disorder of the teeth and supporting structures). The code 276.7 represents a wellknown ADR caused by the drug. The table shows that its causal-leverage is much larger than its reverse causal-leverage, and thus its exclusive causal_leverage is closer to its causalleverage. The code 366.02 was considered by our physicians as neither an ADR nor a medical condition due to drug enalapril. One can see that its causal-leverage and reverse causal-leverage are very close even though either one is larger than the causal-leverage of 276.7. The code 428.0 denotes a medical condition for taking enalapril. The table indicates that its causal-leverage is smaller than its reverse causal-leverage, which results in a negative exclusive causal_ leverage value. The table also includes four other disease conditions that are not related to drug enalapril. That is, they are neither ADRs caused by enalapril nor medical conditions that cause the prescription of enalapril. The code 327.27 has the smallest positive exclusive causal_leverage Table 4 , the rank of this code is as high as 6. This indicates that some unrelated codes could still be ranked high due to the complexity of the data. The codes 275.42 and 525.9 are simply two randomly selected symptoms that are not related to drug enalapril. They exhibit similar properties as codes 366.02 and 327.27. That is, their causal-leverage and reverse causal-leverage values are relatively large, but their absolute values of the exclusive causal_leverage measure are small. Ranking these seven ICD-9 codes using their causal-leverage values, the code 428.0 will demonstrate the strongest causal association with drug enalapril. But if exclusive causal_leverage is used, the code 276.7 (i.e., the known ADR) will have the strongest association with the drug. Therefore, the table indicates that our algorithm can indeed effectively remove some undesirable effects caused by frequent events. For each of the three selected drugs, we computed the exclusive causal-leverage values for all the pairs between the drug and each of the 3,954 ICD-9 codes. We ranked the codes in a decreasing order according to each pair's exclusive causal-leverage value. The top 10 codes were evaluated by our physicians to determine whether they were likely real ADRs associated with the drug. The physicians made decisions based on the Physician's Desk Reference [53] , literature reporting, and their clinical experience. We also ranked the association between the drug and each ICD-9 code using three other measures: causal-leverage, traditional leverage without considering causality, and risk ratio. Risk ratio is defined as the probability that a case coexists with the ICD-9 code relative to the probability that a non-case coexists with the same ICD-9 code. Risk ratio and leverage represent two typical frequency-based interestingness measures. The hazard period was set as T ¼ 90 days when causal-leverage and exclusive causal-leverage were calculated. The value of this parameter needs to be chosen carefully since if it is too large, some unrelated symptoms could form false temporal relationships with the drug. If it is too small, real signals may be excluded because some ADRs only happen after a drug has been taken for as long as tens of days. After balancing these two situations, our physicians think 90 would be an appropriate value for this parameter. Table 4 lists the top 10 ICD-9 codes identified by the exclusive causal-leverage measure for drug enalapril. Eight of them were thought as real ADRs associated with enalapril with high likelihood. Their ranks in the three other measures are also included in the table. One can see that neither risk ratio nor leverage ranked the eight ICD-9 codes high. The table also indicates that the results generated by these two measures (i.e., risk ratio and leverage) are much more similar than those generated by the other two measures. By looking at the ranks of the eight ICD-9 codes, the causal-leverage measure produced much better performance as compared with the risk ratio and leverage measures since it could capture the causal relationship between a pair. Even though the tradition leverage measure obtained comparable or even better ranks for two of the eight ICD-9 codes (i.e., 276.7 and 233.7), it ranked the remaining six ICD-9 codes as low as around 1,000. With capability of reducing the undesirable effects of frequent ICD-9 codes, the exclusive causal-leverage measure achieved the best performance.
Experiment Results
The experiment results for drug pravastatin are given in Table 5 . Seven out of the top 10 ICD-9 codes were identified as likely ADRs by our physicians. The causal-leverage measure gives higher ranks for all these seven ICD-9 codes than both risk ratio and traditional leverage measures. Another interesting observation is that the causal-leverage measure classified three out of the seven ICD-9 codes into its top 10 list. This implies that this measure does have the potential to discover some potential ADRs because of its capability in capturing the causal relationship between a drug and a symptom. Consistently, the exclusive causalleverage measure again achieved the best performance. Table 6 gives the experiment results for drug rosuvastatin. Six out of the top 10 ICD-9 codes were found to be likely ADRs of this drug. In terms of the relative abilities of the four interestingness measures in discovering potential ADRs, these results are consistent with the results demonstrated by the other two drugs.
Since the length of hazard period T affects the performance of our exclusive causal-leverage measure, we tested the rankings of three randomly selected known ADRs of drug enalapril for different T values (Table 7) . Either 30 or 150 does not seem to be appropriate values for T since some known ADRs were ranked very low. Similar rankings were achieved when T was set to 60, 90, or 120 days.
DISCUSSION
The above experiment results showed that our exclusive causal-leverage measure outperformed traditional interestingness measures like risk ratio and leverage because of its ability to capture suspect causal relationships and exclude undesirable effects caused by frequent events. However, due to the complexity, incompleteness, and potential bias (e.g., tolerable ADRs sometimes may not be recorded) of the data, some ICD-9 codes may still be falsely ranked high based on the exclusive causal-leverage. That is, false associations cannot be completely avoided using our method. Please note that, in postmarketing surveillance, data mining is primarily used to shorten the long list of potential drug-ADR pairs. Like the other data mining methods, the signal pairs found by our approach will be subject to further analysis (e.g., epidemiology study), case review, and interpretation by drug safety professionals experienced in the nuances of pharmacoepidemiology and clinical medicine [54] .
When compared to the ADRs from clinical trials, the ADRs identified by the exclusive causal-leverage measure for the statins (pravastatin and rosuvastain) are unique and different. Clinical trials revealed some similar ADRs between the two statins including nausea, headaches, myalgia, and dizziness. However, the ADRs in this study, as listed in Tables 5 and 6 , revealed no overlap of ADRs between the two statins. One reason for this disparity could be that we only evaluated the top 10 symptoms ranked by our measure. The difference may also be accounted by the differences in setting and sampling of cases. Clinical trial data come from double blinded placebo studies, but the hospital data represent a naturalistic study. In clinical trials, the participants are individuals with hyperlipidemia as their only diagnosis or the primary diagnosis, and they are not allowed to have any complicated medication regimen or unstable medical conditions. The data set in our study derived from hospitalized patients, who are primarily male (96.3 percent) with mean age of 68, who normally have multiple diagnoses in various severities and taking variety of medications. As a result, the ADRs derived from the exclusive causal-leverage measure represent more naturalistic and real patients in clinical care. The method allows us to examine and evaluate complicated samples of patients to draw useful causal information.
The focus of this paper is on how to design a novel interestingness measure and apply the result to the important adverse drug reaction problem (i.e., finding interesting ADR signal pairs). Algorithm design and efficiency analysis become more important when one studies how to efficiently mine all possible rare eventsets and association rules based on minimal support. Another difference is that according to the literature, existing rare association rule mining research assumes that all the data are stored in a single table. In contrast, our work must use data from a relational (medical) database composed of several related tables. Although designing efficient SQL statements and data models to handle large volumes of data in a relational database is beyond the scope of this paper, we will consider developing an efficient algorithm suitable for relational databases and analyze its complexity and efficiency in the future.
CONCLUSION
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